<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603407</url>
  </required_header>
  <id_info>
    <org_study_id>U01NS061799</org_study_id>
    <secondary_id>2010-023744-33</secondary_id>
    <secondary_id>U01NS061799</secondary_id>
    <secondary_id>46102316</secondary_id>
    <nct_id>NCT01603407</nct_id>
  </id_info>
  <brief_title>Finding the Optimum Regimen for Duchenne Muscular Dystrophy</brief_title>
  <acronym>FOR-DMD</acronym>
  <official_title>Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare
      three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to
      determine which of the three ways increases muscle strength the most, and which causes the
      fewest side effects. Using the results of this study, the investigators aim to provide
      patients and families with clearer information about the best way to take these drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Boys with Duchenne muscular dystrophy experience progressive muscle weakness as they grow up.
      Corticosteroids are currently the only medicine that has been shown to increase muscle
      strength in boys with DMD. Benefits include an increase in the length of time that boys could
      continue to walk, reduction in the development of curvature of the spine, a longer time of
      adequate breathing, and possible protection against the development of heart problems.

      Doctors have tried different ways of prescribing corticosteroids in order to decrease
      undesirable side effects of the drug. No controlled, long-term study has ever looked at the
      effects of different corticosteroids to see which one improves strength the most and which
      one causes the fewest side effects, over a period of time. Different doctors in different
      countries prescribe the drugs in different ways, and some do not prescribe corticosteroids at
      all.

      The FOR DMD study will enroll boys with DMD ages 4-7. The study will look at three ways of
      taking the following corticosteroids by the mouth to determine which increases muscle
      strength the most, and which causes the fewest side effects:

        1. Prednisone 0.75mg/kg/day

        2. Prednisone 0.75mg/kg/day switching between 10 days on and 10 days off treatment

        3. Deflazacort 0.9mg/kg/day.

      The study will take place at 40 academic medical centers in the United States, Canada, United
      Kingdom, Germany and Italy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three-dimensional (multivariate) outcome</measure>
    <time_frame>See description below</time_frame>
    <description>Three-dimensional outcome consisting of the following three components (each averaged over the Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 visits):
time to stand from lying (log-transformed)
forced vital capacity
subject/parent global satisfaction with treatment, as measured by the Treatment Satisfaction Questionnaire for Medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Once during screening period (1 to 3 months prior to baseline visit), then again at Baseline visit (Month 0), Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>17 Item timed function tests to evaluate the motor ability in ambulant children with DMD. Timed Function Test Grading to differentiate those subjects with similarly fast times who may achieve a ceiling time Total score = Sum of all graded items. Of primary interest will be the average value of these outcomes over all post-baseline visits over the three year follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>Once during screening period (1 to 3 months prior to baseline visit), then again at Baseline visit (Month 0), Month 3, 6, 12, 18, 24, 30 and 36</time_frame>
    <description>Measures the total distance walked in 6 minutes and the number of falls averaged over all post-baseline follow-up visits through Month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of motion (goniometry)</measure>
    <time_frame>Once during screening period (1 to 3 months prior to baseline visit), then again at Baseline visit (Month 0), Month 3, 6, 12, 18, 24, 30 and 36</time_frame>
    <description>Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen tolerance</measure>
    <time_frame>Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60</time_frame>
    <description>Assess the ability to tolerate the starting regimen of corticosteroids, defined as completing 3-5 years of follow-up on study medication with no deviation from the initially prescribed dosage level (increases in dosage band to accommodate growth and weight gain are allowed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile</measure>
    <time_frame>Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60</time_frame>
    <description>The occurrence and severity of the following predictable adverse events (i.e., known side effects of corticosteroids) will be recorded. Behavior problems, bone fractures, cataracts, cushingoid features, GI symptoms, hypertension, immune/adrenal suppression, slow growth (height restriction), skin changes, weight gain, diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline visit (Month 0), Month 3, 6, 12, 18, 24, 30 and 36</time_frame>
    <description>Measured by child self-report (only in children aged 5 years and over) and by proxy (parent(s)/guardian(s)) report for all children. Utilizing Generic Peds QoL (23 questions ) NMD Disease-specific module will be used (25 questions).
The average values of these outcomes over all post-baseline assessments during the three-year follow-up period will be of primary interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function Cardiac function</measure>
    <time_frame>One to three months prior to the baseline visit, then every two years to the age of 10 years, and annually thereafter or at the onset of cardiac signs and symptoms and the year 3 visit</time_frame>
    <description>Monitored by trans-thoracic echocardiogram and 12-lead ECG. The findings will be categorized as: normal; abnormal but not clinically significant;abnormal and clinically significant. The earliest definite, echo detectable impairment of left ventricular function is defined as ejection fraction &lt; 55% and/or fractional shortening &lt; 28%.Monitorred 12-lead ECG. If echocardiogram shows any impaired left ventricular function or evidence of regional motion abnormalities (posterior wall), the interval between evaluations will be reduced and treatment will be initiated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Daily prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily prednisone (0.75 mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily deflazacort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily deflazacort (0.9 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>daily prednisone (0.75 mg/kg/day) tablets for 36-60 months</description>
    <arm_group_label>Daily prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months</description>
    <arm_group_label>Intermittent prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deflazacort</intervention_name>
    <description>daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months</description>
    <arm_group_label>Daily deflazacort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of signed and dated informed consent form.

          -  Confirmed diagnosis of Duchenne muscular dystrophy

          -  Age greater than or equal to 4 years and less than 8 years old

          -  Ability to rise independently from floor, from supine to standing

          -  Willingness and ability to comply with scheduled visits, drug administration plan and
             study procedures

          -  Ability to maintain reproducible FVC measurements.

        Exclusion Criteria:

          -  History of major renal or hepatic impairment, immunosuppression or other
             contraindications to corticosteroid therapy.

          -  History of chronic systemic fungal or viral infections. Acute bacterial
             infection(including TB) would exclude from enrolment until the infection had been
             appropriately treated and resolved.

          -  Diabetes mellitus.

          -  Idiopathic hypercalcuria.

          -  Lack of chicken pox immunity and refusal to undergo immunization.

          -  Evidence of symptomatic cardiomyopathy at screening assessment (one to three months
             prior to the baseline visit). Asymptomatic cardiac abnormality on investigation would
             not be an exclusion.

          -  Current or previous treatment (greater than four consecutive weeks of oral therapy)
             with corticosteroids or other immunosuppressive treatments for DMD or other recurrent
             indications (e.g., asthma), unless approved by FOR-DMD Team (i.e., concurrent
             participation in another allowed DMD trial).

          -  Inability to take tablets, as assessed by the site investigator by the end of the
             screening period (the screening period ranges from one to three months prior to the
             baseline visit).

          -  Allergy/sensitivity to study drugs or their formulations including lactose and/or
             sucrose intolerance.

          -  Severe behavioral problems, including severe autism.

          -  Previous or ongoing medical condition, medical history, physical findings or
             laboratory abnormalities that could affect safety, make it unlikely that treatment and
             follow up will be correctly completed or impair the assessment of study results, in
             the judgment of the site investigator.

          -  Weight of less than 13 kilograms.

          -  Exposure to any investigational drug currently or within 3 months prior to start of
             study treatment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C. Griggs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kate Bushby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA) Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Science Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario (CHEO)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Technical University Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's University Hospital, Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Messina AOU Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. Besta Neurological Institute Foundation</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova School of Medicine</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Center University of Turin</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Infirmary at Leeds</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS2 9NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Glasgow and Clyde NHS Yorkhill Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust Birmingham Heartland's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Genetics, International Centre for Life</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994 Apr;17(4):386-91. Erratum in: Muscle Nerve 1994 Jul;17(7):833.</citation>
    <PMID>8170484</PMID>
  </reference>
  <reference>
    <citation>Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004 Feb 26;2:12.</citation>
    <PMID>14987333</PMID>
  </reference>
  <reference>
    <citation>Bäckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1995 May;5(3):233-41.</citation>
    <PMID>7633189</PMID>
  </reference>
  <reference>
    <citation>Bianchi ML. How to manage osteoporosis in children. Best Pract Res Clin Rheumatol. 2005 Dec;19(6):991-1005. Review.</citation>
    <PMID>16301193</PMID>
  </reference>
  <reference>
    <citation>Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord. 2005 Jan;15(1):80-5.</citation>
    <PMID>15639125</PMID>
  </reference>
  <reference>
    <citation>Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 Jan;138(1):45-50.</citation>
    <PMID>11148511</PMID>
  </reference>
  <reference>
    <citation>Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006 Apr;16(4):249-55. Epub 2006 Mar 20.</citation>
    <PMID>16545568</PMID>
  </reference>
  <reference>
    <citation>Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, Palladino A, Comi LI, Nigro G. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004 Sep;14(8-9):476-82.</citation>
    <PMID>15336688</PMID>
  </reference>
  <reference>
    <citation>Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, Province MA. Clinical investigation in Duchenne dystrophy: 2. Determination of the &quot;power&quot; of therapeutic trials based on the natural history. Muscle Nerve. 1983 Feb;6(2):91-103.</citation>
    <PMID>6343858</PMID>
  </reference>
  <reference>
    <citation>Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT 3rd, Miller JP, Kaiser KK, Florence JM, Pandya S, Signore L, et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol. 1987 Aug;44(8):812-7.</citation>
    <PMID>3632393</PMID>
  </reference>
  <reference>
    <citation>Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989 Apr;39(4):475-81.</citation>
    <PMID>2927672</PMID>
  </reference>
  <reference>
    <citation>Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord. 2004 Sep;14(8-9):526-34.</citation>
    <PMID>15336694</PMID>
  </reference>
  <reference>
    <citation>Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003 Feb;13(2):166-72.</citation>
    <PMID>12565916</PMID>
  </reference>
  <reference>
    <citation>Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan;9(1):77-93. doi: 10.1016/S1474-4422(09)70271-6. Epub 2009 Nov 27. Review.</citation>
    <PMID>19945913</PMID>
  </reference>
  <reference>
    <citation>Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010 Feb;9(2):177-89. doi: 10.1016/S1474-4422(09)70272-8. Epub 2009 Nov 27. Review. Erratum in: Lancet Neurol. 2010 Mar;9(3):237.</citation>
    <PMID>19945914</PMID>
  </reference>
  <reference>
    <citation>Carter GT, McDonald CM. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am J Phys Med Rehabil. 2000 Sep-Oct;79(5):455-8.</citation>
    <PMID>10994887</PMID>
  </reference>
  <reference>
    <citation>Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1015-37. Review.</citation>
    <PMID>12960702</PMID>
  </reference>
  <reference>
    <citation>Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. VI: scales assessing externalizing behaviors. J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1143-70. Review.</citation>
    <PMID>14560165</PMID>
  </reference>
  <reference>
    <citation>Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2002 Dec;12(10):917-25.</citation>
    <PMID>12467746</PMID>
  </reference>
  <reference>
    <citation>Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005 Mar 15;45(6):855-7.</citation>
    <PMID>15766818</PMID>
  </reference>
  <reference>
    <citation>Dubowitz V, Kinali M, Main M, Mercuri E, Muntoni F. Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol. 2002;6(3):153-9.</citation>
    <PMID>12363102</PMID>
  </reference>
  <reference>
    <citation>Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002 Dec;12(10):926-9.</citation>
    <PMID>12467747</PMID>
  </reference>
  <reference>
    <citation>Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, Griggs RC, Brooke MH, Miller JP, Robison J, King W, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991 Dec;41(12):1874-7.</citation>
    <PMID>1745340</PMID>
  </reference>
  <reference>
    <citation>Fenichel GM, Mendell JR, Moxley RT 3rd, Griggs RC, Brooke MH, Miller JP, Pestronk A, Robison J, King W, Signore L, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991 Jun;48(6):575-9.</citation>
    <PMID>2039377</PMID>
  </reference>
  <reference>
    <citation>Follmann D. Multivariate tests for multiple endpoints in clinical trials. Stat Med. 1995 Jun 15;14(11):1163-75. Review.</citation>
    <PMID>7667558</PMID>
  </reference>
  <reference>
    <citation>Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993 Mar;43(3 Pt 1):520-7.</citation>
    <PMID>8450994</PMID>
  </reference>
  <reference>
    <citation>Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991 Apr;48(4):383-8.</citation>
    <PMID>2012511</PMID>
  </reference>
  <reference>
    <citation>Hinton VJ, Nereo NE, Fee RJ, Cyrulnik SE. Social behavior problems in boys with Duchenne muscular dystrophy. J Dev Behav Pediatr. 2006 Dec;27(6):470-6.</citation>
    <PMID>17164619</PMID>
  </reference>
  <reference>
    <citation>Hopke PK, Liu C, Rubin DB. Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the Arctic. Biometrics. 2001 Mar;57(1):22-33.</citation>
    <PMID>11252602</PMID>
  </reference>
  <reference>
    <citation>Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S169-74.</citation>
    <PMID>12206813</PMID>
  </reference>
  <reference>
    <citation>Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab. 1998 Nov;83(11):3795-802.</citation>
    <PMID>9814449</PMID>
  </reference>
  <reference>
    <citation>Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996 Dec;52(4):1324-33.</citation>
    <PMID>8962456</PMID>
  </reference>
  <reference>
    <citation>Loftus J, Allen R, Hesp R, David J, Reid DM, Wright DJ, Green JR, Reeve J, Ansell BM, Woo PM. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics. 1991 Sep;88(3):428-36.</citation>
    <PMID>1881719</PMID>
  </reference>
  <reference>
    <citation>Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004 Oct 15;23(19):2937-60. Erratum in: Stat Med. 2017 Jun 30;36(14 ):2320.</citation>
    <PMID>15351954</PMID>
  </reference>
  <reference>
    <citation>Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD003725.</citation>
    <PMID>15106215</PMID>
  </reference>
  <reference>
    <citation>Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Aug;50(2):317-33. Review.</citation>
    <PMID>8521761</PMID>
  </reference>
  <reference>
    <citation>Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005 Nov-Dec;26(6):768-71.</citation>
    <PMID>15990951</PMID>
  </reference>
  <reference>
    <citation>Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F; North Star Clinical Network for Paediatric Neuromuscular Disease. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 2011 Jun;53(6):535-42. doi: 10.1111/j.1469-8749.2011.03939.x. Epub 2011 Mar 17.</citation>
    <PMID>21410696</PMID>
  </reference>
  <reference>
    <citation>Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592-7.</citation>
    <PMID>2657428</PMID>
  </reference>
  <reference>
    <citation>Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, Franzoni E. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve. 2003 Feb;27(2):222-7.</citation>
    <PMID>12548530</PMID>
  </reference>
  <reference>
    <citation>Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C; Quality Standards Subcommittee of the American Academy of Neurology; Practice Committee of the Child Neurology Society. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005 Jan 11;64(1):13-20.</citation>
    <PMID>15642897</PMID>
  </reference>
  <reference>
    <citation>O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984 Dec;40(4):1079-87.</citation>
    <PMID>6534410</PMID>
  </reference>
  <reference>
    <citation>Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191-4.</citation>
    <PMID>11751186</PMID>
  </reference>
  <reference>
    <citation>Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987 Sep;43(3):487-98.</citation>
    <PMID>3663814</PMID>
  </reference>
  <reference>
    <citation>Quinlivan R, Roper H, Davie M, Shaw NJ, McDonagh J, Bushby K. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord. 2005 Jan;15(1):72-9. Epub 2004 Dec 10.</citation>
    <PMID>15639124</PMID>
  </reference>
  <reference>
    <citation>Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev. 1995;17 Suppl:39-43.</citation>
    <PMID>8882570</PMID>
  </reference>
  <reference>
    <citation>Sansome A, Royston P, Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord. 1993 Sep-Nov;3(5-6):567-9.</citation>
    <PMID>8186713</PMID>
  </reference>
  <reference>
    <citation>Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 2003 Mar 15;91(6):769-72.</citation>
    <PMID>12633823</PMID>
  </reference>
  <reference>
    <citation>Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998 Nov;53(11):949-52.</citation>
    <PMID>10193393</PMID>
  </reference>
  <reference>
    <citation>Stein RE, Jessop DJ. Functional status II(R). A measure of child health status. Med Care. 1990 Nov;28(11):1041-55. Erratum in: Med Care 1991 May;29(5):following 489.</citation>
    <PMID>2250491</PMID>
  </reference>
  <reference>
    <citation>Tang DI, Geller NL, Pocock SJ. On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics. 1993 Mar;49(1):23-30.</citation>
    <PMID>8513104</PMID>
  </reference>
  <reference>
    <citation>Varni JW, Seid M, Knight TS, Uzark K, Szer IS. The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. J Behav Med. 2002 Apr;25(2):175-93.</citation>
    <PMID>11977437</PMID>
  </reference>
  <reference>
    <citation>Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001 Aug;39(8):800-12.</citation>
    <PMID>11468499</PMID>
  </reference>
  <reference>
    <citation>Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999 Feb;37(2):126-39.</citation>
    <PMID>10024117</PMID>
  </reference>
  <reference>
    <citation>Witt WP, Kasper JD, Riley AW. Mental health services use among school-aged children with disabilities: the role of sociodemographics, functional limitations, family burdens, and care coordination. Health Serv Res. 2003 Dec;38(6 Pt 1):1441-66.</citation>
    <PMID>14727782</PMID>
  </reference>
  <reference>
    <citation>Xie H, Heitjan DF. Sensitivity analysis of causal inference in a clinical trial subject to crossover. Clin Trials. 2004 Feb;1(1):21-30. Erratum in: Clin Trials. 2005;2(2):194. Clin Trials. 2004;1(5):2 p following 474.</citation>
    <PMID>16281459</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Robert Griggs, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>prednisone</keyword>
  <keyword>deflazacort</keyword>
  <keyword>muscular dystrophy</keyword>
  <keyword>neuromuscular disease</keyword>
  <keyword>multi-center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deflazacort</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

